Abpro Holdings (ABPO) Preferred Stock Liabilities (2022 - 2025)
Abpro Holdings' (ABPO) quarterly Preferred Stock Liabilities came in at $243000.0 in Q4 2025, up 203.75% YoY from $80000.0 in Q4 2024, and little changed on a QoQ basis from $243000.0 in Q3 2025.
Abpro Holdings (ABPO) Preferred Stock Liabilities (2022 - 2025) Analysis & Trends
Abpro Holdings (ABPO) has 4 years of Preferred Stock Liabilities data on file, last reported at $243000.0 in Q4 2025.
- Quarterly Preferred Stock Liabilities rose 203.75% year-over-year to $243000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $243000.0 (up 203.75% YoY) and the FY2025 annual result came in at $243000.0, up 203.75% from the prior year.
- Preferred Stock Liabilities was little changed at $243000.0 in Q4 2025, from $243000.0 in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $311.7 million in Q1 2023 to a low of $80000.0 in Q4 2024.
- A 4-year average of $106.9 million and a median of $21.9 million in 2023 frame the typical range for Preferred Stock Liabilities.
- Annual changes were most pronounced in 2024 — Preferred Stock Liabilities slumped 99.89% — and 2025, when it surged 203.75%.
- Tracing ABPO's Preferred Stock Liabilities over 4 years: stood at $309.1 million in 2022, then sank by 75.54% to $75.6 million in 2023, then tumbled by 99.89% to $80000.0 in 2024, then surged by 203.75% to $243000.0 in 2025.
- The last three Preferred Stock Liabilities figures came in at $243000.0 (Q4 2025), $243000.0 (Q3 2025), and $93000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 243,000.00 |
| Sep 30, 2025 | 243,000.00 |
| Jun 30, 2025 | 93,000.00 |
| Mar 31, 2025 | 111,000.00 |
| Dec 31, 2024 | 80,000.00 |
| Sep 30, 2024 | 6.13 Mn |
| Jun 30, 2024 | 7.49 Mn |
| Mar 31, 2024 | 7.41 Mn |
| Dec 31, 2023 | 75.60 Mn |
| Sep 30, 2023 | 36.57 Mn |
| Jun 30, 2023 | 36.36 Mn |
| Mar 31, 2023 | 311.65 Mn |
| Dec 31, 2022 | 309.10 Mn |
| Sep 30, 2022 | 307.10 Mn |
| Jun 30, 2022 | 306.00 Mn |
| Mar 31, 2022 | 306.00 Mn |